Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $293.7 million.

  • Cidara Therapeutics' Cash & Equivalents rose 130.52% to $293.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $293.7 million, marking a year-over-year increase of 130.52%. This contributed to the annual value of $189.8 million for FY2024, which is 430.56% up from last year.
  • As of Q3 2025, Cidara Therapeutics' Cash & Equivalents stood at $293.7 million, which was down 42.49% from $510.6 million recorded in Q2 2025.
  • In the past 5 years, Cidara Therapeutics' Cash & Equivalents registered a high of $510.6 million during Q2 2025, and its lowest value of $24.6 million during Q2 2022.
  • Its 3-year average for Cash & Equivalents is $151.4 million, with a median of $127.4 million in 2024.
  • In the last 5 years, Cidara Therapeutics' Cash & Equivalents plummeted by 48.97% in 2022 and then soared by 479.47% in 2025.
  • Cidara Therapeutics' Cash & Equivalents (Quarterly) stood at $59.7 million in 2021, then slumped by 45.16% to $32.7 million in 2022, then increased by 9.31% to $35.8 million in 2023, then soared by 430.56% to $189.8 million in 2024, then skyrocketed by 130.52% to $293.7 million in 2025.
  • Its Cash & Equivalents was $293.7 million in Q3 2025, compared to $510.6 million in Q2 2025 and $168.2 million in Q1 2025.